Sheila DeWitt, Ph.D.
Sheila DeWitt, Ph.D. serves on Wolfe Laboratories’ Board of Advisors. Dr. DeWitt is a life sciences executive and serial entrepreneur with thirty years of experience in biopharmaceutical companies, having founded/co-founded five companies (Diversomer, Orchid, Deuteria Pharmaceuticals, JSD Partners, DeuteRx). She is currently the President and CEO of DeuteRx. Previously, Dr. DeWitt was the President and CEO of Deuteria Pharmaceuticals, the parent company of DeuteRx. Prior to Deuteria, Dr. DeWitt was Vice President of Business Development, Discovery and Manufacturing at EPIX, where she led the $125M merger to transition the company from imaging to therapeutics (EPIX-Predix), led the $28M sale of the 1st FDA approved MRA imaging drug (EPIX-Lantheus), and managed global R&D functions through Phase 2 trials. In addition to numerous publications, patents and presentations, Dr. DeWitt is internationally recognized as a scientific pioneer in combinatorial chemistry (Parke-Davis, Diversomer), and she was recognized by Mass High Tech in its “Women to Watch” list in 2013. She serves on the Industry Advisory Council of ALD Connect, on the Board of Advisors of Gordon-Conwell Theological Seminary and the Biotechnology Advisory Board of Greater Lawrence Technical School. Dr. DeWitt holds her B.A. from Cornell University and Ph.D. in Synthetic Organic Chemistry from Duke University.